2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 570

A Molecular Timeline for Preclinical RA Pathogenesis Defined By Dysregulated PTPN22, Hypercitrullination, and Aberrant Cytokine/Metabolic Profiles in PBMC of at-Risk Individuals
Abstract Number: 736

A Multi-Center, Open Label, Randomized Clinical Tries of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Ankylosing Spondylitis
Abstract Number: 947

A Multi-Center, Open-Label Study to Assess the Pharmacokinetics, Efficacy and Safety of Certolizumab Pegol in Children and Adolescents with Moderately to Severely Active Polyarticular-Course Juvenile Idiopathic Arthritis: Week 24 Results
Abstract Number: 2033

A Multi-Dimensional Genomic Map for Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 446

A Multi-Group Confirmatory Factor Analyses of the Lupuspro Between Southern California and Filipino Samples of Patients with SLE
Abstract Number: 850

A Multicentre Reliability Study of Laser Speckle Contrast Imaging and Thermography in Patients with Raynaud’s Phenomenon Secondary to Systemic Sclerosis
Abstract Number: 942

A Nationwide Experience with the Off Label Use of Interleukin 1 Targeting Treatment in Familial Mediterranean Fever Patients
Abstract Number: 951

A Nationwide Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis. Eleven Months’ Clinical Outcomes from the Danbio Registry
Abstract Number: 3196

A Natural Language Processing System Can Capture Rheumatoid Arthritis Disease Activity Measures in US Veterans Across Multiple Sites
Abstract Number: 1912

A New Avenue of Immune Regulation Conferred By Self-Glycerophospholipids Via Mobilization and Migration of Myeloid-Derived Suppressor Cells
Abstract Number: 944

A New Syndrome in the Spectrum of Cryopyrin-Associated Periodic Syndromes (CAPS) Caused By the Novel R918Q NLRP3 Mutation
Abstract Number: 2295

A Non-Linear Relationship Between Physical Activity and Serum Uric Acid Concentrations: Nhanes 2003-2004
Abstract Number: 835

A Normal Pulmonary Diffusion Capacity Is Rare in Pulmonary Artery Hypertension in Systemic Sclerosis
Abstract Number: 1831

A Novel Graph Theoretic Approach Applied to Modular Repertoire Analysis Identifies a Dual Molecular Progression in Adult SLE Patients, with Distinct Interferon and Neutrophil Transcription Patterns
Abstract Number: 1857

A Novel Highly Selective 5-Hydroxytryptamine 2B (5-HT2B) Receptor Antagonist Ameliorating Fibrosis in Preclinical Models of Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].